Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | LYN | P07948 | 3/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SYK | P43405 | 2/20 | 0.94 |
| ▸ | PLK4 | O00444 | 1/20 | 0.94 |
| ▸ | DDX3X | O00571 | 1/20 | 0.94 |
| ▸ | GAK | O14976 | 1/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.94 |
| ▸ | CA12 | O43570 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL8217 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1060852 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1673189 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL726190 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15632914 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29370699 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1440465 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1439360 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL5004429 | 0.99 | ABL1 (0.97) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859559 | 0.97 | ABL1 (0.94) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3746059-B1 | COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-04 | — | — | EP | claimed |
| US-20260000769-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-01-01 | — | — | US | claimed |
| US-20250352510-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-11-20 | — | — | US | claimed |
| EP-3413978-B1 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS | INST NAT SANTE RECH MED (FR) | 2025-11-12 | — | — | EP | claimed |
| US-20250325671-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-10-23 | — | — | US | claimed |
| US-20250312461-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-10-09 | — | — | US | claimed |
| US-20250213522-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-07-03 | — | — | US | claimed |
| EP-4578865-A2 | LYMPH DIRECTING PRODRUGS | Monash University (AU) | 2025-07-02 | — | — | EP | claimed |
| CN-120081908-A | Multifunctional probe based on protein dynamic combination and preparation and application thereof | 莎穆(上海)生物科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-3324856-B1 | SHEAR-THINNING COMPOSITIONS AS AN INTRAVASCULAR EMBOLIC AGENT | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-04-23 | — | — | EP | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | claimed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | claimed |
| EP-3560959-B1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-11-22 | — | — | EP | claimed |
| EP-2896401-B1 | TARGETED DRUG DELIVERY SYSTEM FOR POORLY SOLUBLE DRUG | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-04-12 | — | — | EP | claimed |
| EP-3674302-B1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE HOLDINGS CORP (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3544685-B1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEV CT BIOTECHNOLOGY (TW) | 2023-01-04 | — | — | EP | claimed |
| EP-2753334-B1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TUFTS COLLEGE (US) | 2022-10-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000769-A1 | LYMPH DIRECTING PRODRUGS | LIPA, MALT1, SLCO2A1 | ABL1 2786/4885BCR 206/4885KIT 2252/4885 |
| US-20250312461-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | ABL1 1987/4885BCR 448/4885KIT 1810/4885 |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MALT1, CES1, LIPA | ABL1 2512/4885BCR 156/4885KIT 2849/4885 |
| US-20250325671-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | ABL1 1987/4885BCR 448/4885KIT 1810/4885 |
| US-20250213522-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | ABL1 1987/4885BCR 448/4885KIT 1810/4885 |
| US-20250352510-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | ABL1 1987/4885BCR 448/4885KIT 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.